Revvity (RVTY) Competitors

Revvity logo
$148.66 -5.73 (-3.71%)
Closing price 03:59 PM Eastern
Extended Trading
$148.90 +0.24 (+0.16%)
As of 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RVTY vs. BRKR, TECH, A, BIO, and CRL

Should you buy Revvity stock or one of its competitors? Revvity's main competitors and comparable companies include Bruker (BRKR), Bio-Techne (TECH), Agilent Technologies (A), Bio-Rad Laboratories (BIO), and Charles River Laboratories International (CRL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Revvity compare to Bruker?

Revvity (NYSE:RVTY) and Bruker (NASDAQ:BRKR) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

In the previous week, Revvity had 6 more articles in the media than Bruker. MarketBeat recorded 8 mentions for Revvity and 2 mentions for Bruker. Revvity's average media sentiment score of 1.03 beat Bruker's score of 0.80 indicating that Revvity is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revvity
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bruker
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Revvity presently has a consensus target price of $133.86, indicating a potential downside of 13.42%. Bruker has a consensus target price of $60.57, indicating a potential downside of 1.65%. Given Bruker's stronger consensus rating and higher possible upside, analysts plainly believe Bruker is more favorable than Revvity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revvity
0 Sell rating(s)
13 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.32
Bruker
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
2.57

Revvity has a net margin of 8.61% compared to Bruker's net margin of -3.82%. Bruker's return on equity of 13.76% beat Revvity's return on equity.

Company Net Margins Return on Equity Return on Assets
Revvity8.61% 8.64% 5.24%
Bruker -3.82%13.76%5.47%

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.3%. Revvity pays out 12.4% of its earnings in the form of a dividend. Bruker pays out -18.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bruker is clearly the better dividend stock, given its higher yield and lower payout ratio.

Revvity has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Bruker has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Revvity has higher earnings, but lower revenue than Bruker. Bruker is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revvity$2.86B6.04$241.20M$2.2668.41
Bruker$3.44B2.74-$8.60M-$1.10N/A

86.7% of Revvity shares are held by institutional investors. Comparatively, 79.5% of Bruker shares are held by institutional investors. 0.9% of Revvity shares are held by insiders. Comparatively, 27.2% of Bruker shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Bruker beats Revvity on 10 of the 19 factors compared between the two stocks.

How does Revvity compare to Bio-Techne?

Revvity (NYSE:RVTY) and Bio-Techne (NASDAQ:TECH) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

86.7% of Revvity shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 0.9% of Revvity shares are held by insiders. Comparatively, 1.3% of Bio-Techne shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Revvity has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market.

Revvity presently has a consensus target price of $133.86, indicating a potential downside of 13.42%. Bio-Techne has a consensus target price of $68.92, indicating a potential downside of 5.33%. Given Bio-Techne's higher possible upside, analysts plainly believe Bio-Techne is more favorable than Revvity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revvity
0 Sell rating(s)
13 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.32
Bio-Techne
1 Sell rating(s)
14 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.12

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.4%. Revvity pays out 12.4% of its earnings in the form of a dividend. Bio-Techne pays out 29.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Revvity had 1 more articles in the media than Bio-Techne. MarketBeat recorded 8 mentions for Revvity and 7 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.14 beat Revvity's score of 1.03 indicating that Bio-Techne is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revvity
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bio-Techne
2 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Revvity has higher revenue and earnings than Bio-Techne. Bio-Techne is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revvity$2.86B6.04$241.20M$2.2668.41
Bio-Techne$1.22B9.41$181.86M$1.0966.79

Bio-Techne has a net margin of 13.95% compared to Revvity's net margin of 8.61%. Bio-Techne's return on equity of 13.00% beat Revvity's return on equity.

Company Net Margins Return on Equity Return on Assets
Revvity8.61% 8.64% 5.24%
Bio-Techne 13.95%13.00%10.57%

Summary

Bio-Techne beats Revvity on 12 of the 19 factors compared between the two stocks.

How does Revvity compare to Agilent Technologies?

Revvity (NYSE:RVTY) and Agilent Technologies (NYSE:A) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.6%. Revvity pays out 12.4% of its earnings in the form of a dividend. Agilent Technologies pays out 20.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has increased its dividend for 9 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Agilent Technologies had 2 more articles in the media than Revvity. MarketBeat recorded 10 mentions for Agilent Technologies and 8 mentions for Revvity. Revvity's average media sentiment score of 1.03 beat Agilent Technologies' score of 0.46 indicating that Revvity is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revvity
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Agilent Technologies
6 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

86.7% of Revvity shares are held by institutional investors. Comparatively, 87.4% of Agilent Technologies shares are held by institutional investors. 0.9% of Revvity shares are held by company insiders. Comparatively, 0.2% of Agilent Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Agilent Technologies has higher revenue and earnings than Revvity. Agilent Technologies is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revvity$2.86B6.04$241.20M$2.2668.41
Agilent Technologies$7.37B6.65$1.30B$5.0834.25

Revvity currently has a consensus target price of $133.86, indicating a potential downside of 13.42%. Agilent Technologies has a consensus target price of $181.45, indicating a potential upside of 4.29%. Given Agilent Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Agilent Technologies is more favorable than Revvity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revvity
0 Sell rating(s)
13 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.32
Agilent Technologies
0 Sell rating(s)
4 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.82

Agilent Technologies has a net margin of 19.53% compared to Revvity's net margin of 8.61%. Agilent Technologies' return on equity of 24.45% beat Revvity's return on equity.

Company Net Margins Return on Equity Return on Assets
Revvity8.61% 8.64% 5.24%
Agilent Technologies 19.53%24.45%13.09%

Revvity has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

Summary

Agilent Technologies beats Revvity on 16 of the 19 factors compared between the two stocks.

How does Revvity compare to Bio-Rad Laboratories?

Revvity (NYSE:RVTY) and Bio-Rad Laboratories (NYSE:BIO) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Bio-Rad Laboratories has a net margin of 39.45% compared to Revvity's net margin of 8.61%. Revvity's return on equity of 8.64% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Revvity8.61% 8.64% 5.24%
Bio-Rad Laboratories 39.45%3.58%2.51%

Bio-Rad Laboratories has lower revenue, but higher earnings than Revvity. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revvity$2.86B6.04$241.20M$2.2668.41
Bio-Rad Laboratories$2.58B3.82$759.90M$37.979.65

86.7% of Revvity shares are held by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are held by institutional investors. 0.9% of Revvity shares are held by company insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Revvity presently has a consensus target price of $133.86, suggesting a potential downside of 13.42%. Bio-Rad Laboratories has a consensus target price of $366.67, suggesting a potential upside of 0.02%. Given Bio-Rad Laboratories' higher probable upside, analysts clearly believe Bio-Rad Laboratories is more favorable than Revvity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revvity
0 Sell rating(s)
13 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.32
Bio-Rad Laboratories
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20

In the previous week, Bio-Rad Laboratories had 4 more articles in the media than Revvity. MarketBeat recorded 12 mentions for Bio-Rad Laboratories and 8 mentions for Revvity. Revvity's average media sentiment score of 1.03 beat Bio-Rad Laboratories' score of 0.10 indicating that Revvity is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revvity
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bio-Rad Laboratories
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Revvity has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Summary

Revvity beats Bio-Rad Laboratories on 10 of the 16 factors compared between the two stocks.

How does Revvity compare to Charles River Laboratories International?

Charles River Laboratories International (NYSE:CRL) and Revvity (NYSE:RVTY) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 86.7% of Revvity shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by insiders. Comparatively, 0.9% of Revvity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Charles River Laboratories International had 1 more articles in the media than Revvity. MarketBeat recorded 9 mentions for Charles River Laboratories International and 8 mentions for Revvity. Revvity's average media sentiment score of 1.03 beat Charles River Laboratories International's score of 0.93 indicating that Revvity is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Charles River Laboratories International
6 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Revvity
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Charles River Laboratories International has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market. Comparatively, Revvity has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Charles River Laboratories International presently has a consensus target price of $311.67, suggesting a potential downside of 7.86%. Revvity has a consensus target price of $133.86, suggesting a potential downside of 13.42%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, analysts plainly believe Charles River Laboratories International is more favorable than Revvity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Charles River Laboratories International
1 Sell rating(s)
3 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.71
Revvity
0 Sell rating(s)
13 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.32

Revvity has a net margin of 8.61% compared to Charles River Laboratories International's net margin of 1.01%. Charles River Laboratories International's return on equity of 16.95% beat Revvity's return on equity.

Company Net Margins Return on Equity Return on Assets
Charles River Laboratories International1.01% 16.95% 6.93%
Revvity 8.61%8.64%5.24%

Revvity has lower revenue, but higher earnings than Charles River Laboratories International. Revvity is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories International$3.98B4.08-$144.34M$0.91371.73
Revvity$2.86B6.04$241.20M$2.2668.41

Summary

Charles River Laboratories International beats Revvity on 11 of the 16 factors compared between the two stocks.

Get Revvity News Delivered to You Automatically

Sign up to receive the latest news and ratings for RVTY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVTY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RVTY vs. The Competition

MetricRevvityLife Sciences Tools & Services IndustryHealthcare SectorNYSE Exchange
Market Cap$16.60B$10.83B$7.83B$23.18B
Dividend Yield0.18%1.45%2.47%3.78%
P/E Ratio65.7851.4934.3229.41
Price / Sales5.647.118.003.24
Price / Cash17.5126.7921.0215.64
Price / Book2.325.804.764.04
Net Income$241.20M$57.47B$3.52B$1.08B
7 Day Performance-7.65%-5.43%-5.35%-3.09%
1 Month Performance-2.56%-0.97%-3.62%-1.21%
1 Year Performance60.47%18.51%-0.62%5.64%

Revvity Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RVTY
Revvity
2.6915 of 5 stars
$148.66
-3.7%
$134.21
-9.7%
+66.9%$16.60B$2.94B65.7811,000
BRKR
Bruker
2.4639 of 5 stars
$66.54
+8.5%
$60.57
-9.0%
+48.0%$9.72B$3.44BN/A11,085
TECH
Bio-Techne
2.1735 of 5 stars
$72.83
+0.1%
$68.92
-5.4%
+22.6%$11.42B$1.22B42.283,000
A
Agilent Technologies
3.7705 of 5 stars
$180.09
+3.0%
$181.45
+0.8%
+18.4%$49.95B$6.95B35.4518,100
BIO
Bio-Rad Laboratories
1.5007 of 5 stars
$388.18
+1.7%
$366.67
-5.5%
+16.7%$10.16B$2.58B10.227,450

Related Companies and Tools


This page (NYSE:RVTY) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners